These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9604916)

  • 1. Assessment of effects of lipid-lowering drugs on hemostasis.
    Altman R
    Am J Cardiol; 1998 Apr; 81(8A):73F-74F. PubMed ID: 9604916
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
    Szapáry L; Horváth B; Márton Z; Fehér G; Tóth K; Komoly S
    Orv Hetil; 2008 Jun; 149(24):1117-23. PubMed ID: 18539578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of a new hypolipemic preparation fluvastatin (Lescol) on rheological indices and hemostatic parameters].
    Filippova VG; Mantsurova AV; Zadionchenko VS; Zaporozhets TP
    Ter Arkh; 1997; 69(4):43-5. PubMed ID: 9213958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihyperlipidemic capsules in the treatment of hyperlipidemia and its clinical effect on hemorheology and aggregation of thrombocytes.
    Hu XC; Cai FX; Tian JC; Feng XQ; Ma L
    J Tradit Chin Med; 1989 Sep; 9(3):199-202. PubMed ID: 2615457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of lipid-regulating therapy on haemostatic parameters.
    Milionis HJ; Elisaf MS; Mikhailidis DP
    Curr Pharm Des; 2003; 9(29):2425-43. PubMed ID: 14529557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Getting the skinny on lipid-lowering drugs.
    Kuncl N; Nelson KM
    Nursing; 2000 Jul; 30(7):52-3. PubMed ID: 10983101
    [No Abstract]   [Full Text] [Related]  

  • 7. Recommendations for Phase IV studies in the development of lipid-lowering drugs.
    Gregg RE
    Am J Cardiol; 1998 Apr; 81(8A):64F-66F. PubMed ID: 9604913
    [No Abstract]   [Full Text] [Related]  

  • 8. Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
    Shepherd J; Olsson AG; Sacks FM; Black DM; Orloff DG; Bilheimer DW
    Am J Cardiol; 1998 Apr; 81(8A):88F-94F. PubMed ID: 9604922
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of refined konjac meal on lipid metabolism and blood viscosity of rats fed by high fat forage].
    Wang Z; Yang L; Liu H; Tan X
    Wei Sheng Yan Jiu; 2002 Apr; 31(2):120-1. PubMed ID: 12561549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipids and Cardiovascular Disease: Putting It All Together.
    Pownall HJ; Gotto AM
    Methodist Debakey Cardiovasc J; 2019; 15(1):5-8. PubMed ID: 31049143
    [No Abstract]   [Full Text] [Related]  

  • 11. Implications of 4S evidence on baseline lipid levels.
    Ravnskov U
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats.
    Deng ZY; Shan WG; Wang SF; Hu MM; Chen Y
    Pharm Biol; 2017 Dec; 55(1):663-672. PubMed ID: 27951728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influences of lipid-modifying agents on hemostasis.
    Sirtori CR; Colli S
    Cardiovasc Drugs Ther; 1993 Nov; 7(5):817-23. PubMed ID: 8110626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 3-glucosaminoglycan sulfate on hemorheologic parameters in hyperlipidemic peripheral vascular disease (PVD) patients: a preliminary double-blind crossover study.
    Ciuffetti G; Mercuri M; Susta A; Lupattelli G; Pasqualini L; Lombardini R; Mannarino E
    Angiology; 1989 Apr; 40(4 Pt 1):255-9. PubMed ID: 2705632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.
    Zambrana JL; Velasco F; Castro P; Concha M; Vallés F; Montilla P; Jimenéz-Perepérez JA; López-Miranda J; Pérez-Jiménez F
    Am J Cardiol; 1997 Oct; 80(7):836-40. PubMed ID: 9381994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure.
    Tziomalos K; Karagiannis A; Athyros VG
    Curr Pharm Des; 2014; 20(40):6306-13. PubMed ID: 24953388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of pyridinolcarbamate (anginin) on blood coagulation, fibrinolysis and thrombocytes].
    Goossens N
    Thromb Diath Haemorrh Suppl; 1973; 55():273-84. PubMed ID: 4804076
    [No Abstract]   [Full Text] [Related]  

  • 18. On the hypolipemic properties of bendaline.
    Marmo E; Lampa E; Matera MG; Spadaro R; Romano AR; Guarino V
    J Med; 1984; 15(2):105-25. PubMed ID: 6595341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipids in liver transplant recipients.
    Hüsing A; Kabar I; Schmidt HH
    World J Gastroenterol; 2016 Mar; 22(12):3315-24. PubMed ID: 27022213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
    Idzior-Waluś B
    Przegl Lek; 2001; 58(10):924-7. PubMed ID: 11957820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.